Table 2.

The levles of initial glycans from NC, MCI, and dementia patients.

GPs	NC (n = 81)	MCI (n = 108)	Dementia (n = 81)	p*
	Median (P25–P75)	Median (P25–P75)	Median (P25–P75)
GP1	0.05 (0.02–0.20)	0.37 (0.16–0.60)	0.33 (0.22–0.57)#$	<0.001
GP2	0.28 (0.10–0.45)	0.37 (0.17–0.73)	0.45 (0.24–0.78)#$	0.001
GP4	42.02 (34.75–47.92)	41.59 (34.85–47.32)	39.16 (34.28–45.70)a	0.575
GP5	0.00 (0.00–0.02)	0.05 (0.01–0.17)	0.20 (0.07–0.36)#&$	<0.001
GP6	6.22 (4.76–7.78)	6.23 (5.17–7.52)	6.51 (5.21–7.73)a	0.937
GP7	0.01 (0.00–0.05)	0.14 (0.05–0.27)	0.15 (0.05–0.40)#$	<0.001
GP8	11.53 (10.35–12.87)	12.35 (10.02–13.91)	14.46 (13.11–15.57)#&	<0.001
GP9	2.97 (1.72–4.64)	3.35 (2.00–5.06)	4.29 (3.29–5.58)#&	<0.001
GP10	0.73 (0.52–1.13)	1.11 (0.57–1.93)	2.12 (1.19–2.87)#&$	<0.001
GP11	0.08 (0.06–0.23)	0.31 (0.14–0.60)	0.10 (0.05–0.31)&$	<0.001
GP12	0.14 (0.04–0.32)	0.16 (0.08–0.31)	0.32 (0.17–0.58)#&	<0.001
GP13	0.14 (0.04–0.32)	0.31 (0.15–0.76)	0.36 (0.25–0.73)#$	<0.001
GP14	13.73 (11.43–17.54)	13.02 (8.74–16.56)	11.24 (7.89–14.26)a#	0.001
GP15	0.11 (0.06–0.18)	0.21 (0.11–0.43)	0.45 (0.23–0.68)#&$	<0.001
GP16	3.97 (2.96–4.64)	3.66 (2.99–4.49)	2.93 (2.34–3.46)a#&	<0.001
GP17	0.83 (0.51–1.20)	0.56 (0.34–0.90)	0.75 (0.57–1.12)&$	<0.001
GP18	10.52 (7.73–13.29)	9.27 (7.75–12.12)	7.2 (5.89–9.06)#&	<0.001
GP19	1.76 (1.28–2.24)	1.86 (1.31–2.42)	1.77 (1.29–2.12)	0.429
GP21	0.23 (0.17–0.31)	0.18 (0.13–0.26)	0.32 (0.23–0.53)#&$	<0.001
GP22	0.07 (0.46–0.14)	0.14 (0.07–0.27)	0.11 (0.08–0.24)#$	<0.001
GP23	0.67 (0.42–1.03)	0.53 (0.34–0.82)	0.84 (0.50–1.10)&$	<0.001
GP24	0.82 (0.59–1.33)	0.83 (0.49–1.21)	0.76 (0.47–1.05)	0.449

NC normal cognitive functioning, MCI mild cognitive impairment.

*p < 0.05 was considered statistically significant.

^#p < 0.017, Dementia group compared with NC group.

^$p < 0.017, MCI group compared with NC group.

^&p < 0.017, Dementia group compared with MCI group.

^aAnalysis of variance (ANOVA).